[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.166.22. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
April 1986

Pentoxifylline (Trental) Therapy for the Vasculitis of Atrophie Blanche

Author Affiliations

6400 Prospect Ave Kansas City, MO 64132

Arch Dermatol. 1986;122(4):380-381. doi:10.1001/archderm.1986.01660160030012
Abstract

To the Editor.—  Pentoxifylline (Trental) has been used worldwide since 1972 for the treatment of intermittent claudication. In 1984, the US Food and Drug Administration approved the release of this medication for use in the United States. This drug lowers the blood viscosity and improves erythrocyte flexibility. These effects allow increased blood flow to ischemic tissues.In November 1984, a 46-year-old man who had severe atrophie blanche with leukocytoclastic vasculitis for five years brought me a newspaper clipping about pentoxifylline therapy. His problem had been studied and a biopsy performed. The condition was only partially controlled with the administration of oral prednisone. The disease resulted in a multitude of small painful ulcers with crusts and scaling that extended from the foot almost to his knees.Pentoxifylline therapy was begun with a dosage of 400 mg twice a day for three days, then the dosage was changed to three tablets per

First Page Preview View Large
First page PDF preview
First page PDF preview
×